Pfizer Inc.
PFE · Healthcare · Pharmaceuticals
Updated 24 min ago · data delayed ≥15 min
IconicScore
ProprietaryRanked #76 of 500 by Iconic Score · #10 of 59in its sector. IconicAlpha’s proprietary brand-intelligence metric — a multi-model blend of scale, market attention, category leadership, and AI-analyzed brand visibility.
Get the free morning email
The biggest IconicScore™ gainer and loser, plus the strongest and weakest sectors, in your inbox before the open. See a sample →
Price performance
Export history · AnalystThis insight is part of the Analyst tier — unlock the IconicScore vs. price overlay, side-by-side comparison, and CSV export.
Upgrade to AnalystThis is part of the Enterprise tier — benchmark your IconicScore against sector peers, claim your profile, and manage how your brand appears on the wall.
Upgrade to EnterpriseIconic Profile
Pfizer Inc. (PFE) is a leading global biopharmaceutical company specializing in the research, development, and manufacturing of innovative medicines and vaccines across various therapeutic areas, including oncology, cardiology, immunology, and infectious diseases. With a market capitalization of $137.8 billion, Pfizer holds a significant position in the healthcare sector, driven by its robust product pipeline and strategic collaborations. The company gained widespread recognition for its COVID-19 vaccine, developed in partnership with BioNTech, which has significantly impacted public health and solidified its reputation as a key player in vaccine development. Pfizer’s commitment to advancing healthcare solutions and addressing unmet medical needs underscores its importance in the pharmaceutical industry, making it a critical contributor to global health outcomes and a prominent entity in the evolving landscape of biopharmaceutical innovation.
IconicOracleAI™ Brief
Pfizer Inc's Iconic Score of 62 reflects a stable brand presence amidst competitive pressures in the biopharmaceutical sector. The company's strong brand-visibility signal of 90/100 indicates effective logo recognition, although recent headlines focusing on rivals like Regeneron and Bristol Myers Squibb highlight the challenges and scrutiny faced by major players in the industry. The slight decline in stock price suggests market sensitivity to these competitive dynamics, contributing to the current sentiment around Pfizer.
AI-generated explanation of current score drivers. Not investment advice.
Enterprise tier: claim your logo to manage how your brand is represented.